Anti-CA19-9 Mouse Antibody [C17A13]

Catalog No.: F2466

Application: Reactivity: Human

Usage Information

Dilution
IHC1:100

Application
IHC, FCM, ELISA

Reactivity
Human

Source
Mouse

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Positive Control	Human colorectal adenocarcinoma
Negative Control

Datasheet & SDS

Biological Description

Specificity
CA19-9 Mouse mAb detects endogenous levels of CA 19-9 protein.

Clone
C17A13

Synonym(s)
CA19.9, Ovarian tumor antigen, Pancreatic tumor antigen, Sialyl Lewis a

Background
CA19-9 (Carbohydrate antigen 19-9), also known as Sialyl Lewis A (sLeᵃ), is a sialylated Lewis blood group antigen, a tetrasaccharide glycan epitope composed of sialic acid, galactose, N-acetylglucosamine, and fucose, biosynthesized via the Lewis blood group pathway and requiring a functional Lewis antigen for its formation. CA19-9 is expressed on glycoproteins and glycolipids of epithelial cell membranes, particularly in the pancreas, biliary tract, stomach, and colon, and can be shed into the bloodstream. It is the current gold-standard serum biomarker for pancreatic adenocarcinoma. Functionally, CA19-9 serves as a biomarker (for diagnosis, prognosis, monitoring treatment response, and detecting recurrence), a predictor (correlating with tumor burden, stage, and resectability), and a promoter of cancer progression by facilitating E-selectin–mediated adhesion, enhancing angiogenesis, modulating immune responses, and influencing tumor microenvironment interactions. Beyond pancreatic cancer, CA19-9 is elevated in other gastrointestinal malignancies and certain benign diseases, and is under investigation as a therapeutic target via antibodies, vaccines, biosynthesis inhibitors, and CA19-9–guided drug delivery systems.

Background

CA19-9 (Carbohydrate antigen 19-9), also known as Sialyl Lewis A (sLeᵃ), is a sialylated Lewis blood group antigen, a tetrasaccharide glycan epitope composed of sialic acid, galactose, N-acetylglucosamine, and fucose, biosynthesized via the Lewis blood group pathway and requiring a functional Lewis antigen for its formation. CA19-9 is expressed on glycoproteins and glycolipids of epithelial cell membranes, particularly in the pancreas, biliary tract, stomach, and colon, and can be shed into the bloodstream. It is the current gold-standard serum biomarker for pancreatic adenocarcinoma. Functionally, CA19-9 serves as a biomarker (for diagnosis, prognosis, monitoring treatment response, and detecting recurrence), a predictor (correlating with tumor burden, stage, and resectability), and a promoter of cancer progression by facilitating E-selectin–mediated adhesion, enhancing angiogenesis, modulating immune responses, and influencing tumor microenvironment interactions. Beyond pancreatic cancer, CA19-9 is elevated in other gastrointestinal malignancies and certain benign diseases, and is under investigation as a therapeutic target via antibodies, vaccines, biosynthesis inhibitors, and CA19-9–guided drug delivery systems.

References
https://pubmed.ncbi.nlm.nih.gov/32827580/ https://pubmed.ncbi.nlm.nih.gov/30814526/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%